Authors: Stephanie Wonnell Yencho, Jared Austin, Eric Betka, Derek Gyori, Christine Cassidy, Laura Stanbery, Phylicia Aaron, Charles Brunicardi, Gerald Edelman, Lance Dworkin, John Nemunaitis.
Recent advances in comprehensive genomic profiling (CGP) has enabled the detection of actionable mutations with corresponding molecular targeted therapy, both rapidly and accurately. While the cost of CGP has declined, it is still unknown how CGP through use of targeted precision therapy effects health care costs. We present evidence for use of CGP in advanced cancer management and corresponding precision therapy to reduce total healthcare utilization.
View/Download pdf